Ferring Continues Peptide Development With Enteris

Enteris BioPharma Initiates Feasibility Program with Ferring Pharmaceuticals to Develop an Oral Formulation of a Peptide

Agreement to Target New Oral Peptide Development Opportunity, Extending Successful Relationship between Enteris and Ferring

BOONTON, NJ – March 5, 2018Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, announced today that it has entered into a feasibility development agreement with Ferring Pharmaceuticals to utilize Enteris’ proprietary oral peptide delivery platform, Peptelligence®, to develop an oral formulation of a peptide-based injectable therapeutic from Ferring.

Under the terms of the agreement, Enteris will conduct feasibility studies to develop an oral formulation of an undisclosed peptide therapeutic from Ferring. Based on the results of the feasibility program, Ferring will have the option to license the oral tablet formulation from Enteris. This new agreement between Enteris and Ferring adds to several ongoing projects between the two companies, including a licensing agreement announced in January 2017.

Joel Tune, Chief Executive Officer and Executive Chairman of Enteris BioPharma, remarked, “We are very pleased to extend our relationship with Ferring and explore the potential of Peptelligence to successfully enable the oral delivery of this peptide therapeutic. For Enteris, this latest agreement comes at time of significant growth as we continue to advance our internal pipeline, led by Ovarest®, and target additional opportunities to leverage the power of Peptelligence to enable the oral delivery of peptide-based medications that must otherwise be administered by injection.”

Alan Harris, Senior Vice President, R&D Executive Office of Ferring Pharmaceuticals, said, “The oral delivery of peptides offers a significant opportunity to provide additional therapeutic choices to patients, while serving to maximize the market potential of peptide-based therapeutics. We continue to be impressed with Enteris’ proprietary oral delivery technology and look forward to working with them on this new development program.”

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalised healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit http://www.ferring.com.

About Enteris BioPharma

Enteris BioPharma, Inc. is a privately held, New Jersey-based biotechnology company offering innovative formulation solutions built around its proprietary drug delivery technologies. The Company’s proprietary oral delivery technology – Peptelligence® – has been the subject of numerous feasibility studies and active development programs, several of which are in late stage clinical development. Additionally, Enteris BioPharma is advancing an internal product pipeline of oral tablet reformulations of drug products that address significant treatment opportunities for which there is no oral delivery option. Enteris BioPharma’s most advanced internal product candidate, Ovarest® (oral leuprolide tablet), is an oral peptide being developed for the treatment of endometriosis. Tobrate® (oral tobramycin tablet) is also being developed by Enteris BioPharma for the treatment of uncomplicated urinary tract infection (uUTI). A third internal compound, octreotide, will be entering preclinical development in 2018. For more information on Enteris BioPharma and its proprietary oral delivery technology, please visit https://www.EnterisBioPharma.com.

  For Enteris BioPharma: Enteris Media Relations:
Brian Zietsman, President & CFO
Jason Rando
Tiberend Strategic Advisors, Inc.